

PULSAR Subgroup Analysis: Aflibercept 8 mg Efficacy in CNV Subtypes Including PCV over 96 Weeks with Ability to Extend Dosing Intervals to >16 Weeks

Andrew A. Moshfeghi

Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

Rufino Silva,¹ Tien Yin Wong,² Chui Ming Gemmy Cheung,³ Jeffrey S Heier,⁴ Won Ki Lee,⁵ Tomohiro lida,⁶ Xin Zhang,⁷ Tobias Machewitz,⁸ Andrea Schulze,⁸ and Sergio Leal,⁷ on behalf of the PULSAR study investigators

¹Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Ophthalmology Department, Coimbra Hospital and University Centre, Portugal; Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal; ²Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Tsinghua Medicine, Tsinghua University, Beijing, China; ³Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore; ⁴Ophthalmic Consultants of Boston, Boston, MA, USA; ⁵Nune Eye Hospital, Seoul, Republic of Korea; ⁶Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan; ⁷Bayer Consumer Care AG, Basel, Switzerland; ⁸Bayer AG, Berlin, Germany

Financial Disclosures:


AAM has received consulting fees from Allergan, Graybug, Novartis, Ocular Therapeutix, Pr3vent, Regeneron Pharmaceuticals, Inc., Regenxbio, Roche/Genentech, Valitor, and Waldo; performed contracted research with Novartis, Regeneron Pharmaceuticals, Inc., and Roche/Genentech; and received ownership interest in Ocular Therapeutix, PLACID0, Pr3vent, and Waldo. The PULSAR study (NCT04423718) was sponsored by Bayer AG (Leverkusen, Germany) and co-funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation. Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (*Ann Intern Med* 2022;175:1298–1304).



METHODS

PULSAR: 2-year multicenter, randomized, double-masked study (NCT04423718)

- PULSAR was a global study conducted across 223 sites in 27 countries
- ICGA was optional and conducted in 296 patients^a in 13 countries; data from 139 patients with ICGA-confirmed PCV are reported here



• **Primary endpoint:** Mean change in BCVA from baseline at Week 48 (4-letter non-inferiority vs 2q8)


- In Year 1, only dosing interval shortening was allowed
- In Year 2, dosing interval shortening AND extension were allowed


^aPCV could not be graded in 3 patients. **q8**, every 8 weeks; **q12**, every 12 weeks; **q16**, every 16 weeks; **BCVA**, best-corrected visual acuity; **ICGA**, indocyanine green angiography; **nAMD**, neovascular age-related macular degeneration; **PCV**, polypoidal choroidal vasculopathy.




RESULTS

From BL to Week 96	2q8 (n=54)	8q12 (n=44)	8q16 (n=41)
Mean (95% CI) change in BCVA (ETDRS letters) ^a	+9.6	+8.4	+8.2
	(6.3, 12.9)	(4.5, 12.3)	(5.4, 11.1)
Mean (95% CI) change in	-157	-172	-145
CRT (µm)ª	(-195, -118)	(-215, -130)	(-190, -100)
Mean±SD total injections ^b	12.7±0.7	9.7±1.4	7.7±1.2







^aFAS, LOCF. ^bW96 completers only: 2q8, n=49; 8q12, n=40; 8q16, n=36; percentages calculated based on number of completers who underwent assessment. ^cW48, n=44 (2q8) and n=69 (All 8 mg); at W96, n=47 (2q8) and n=71 (All 8 mg). ^dW48, n=44 (2q8) and n=69 (All 8 mg); at W96, n=47 (2q8) and n=71 (All 8 mg). ^dW48, n=44 (2q8) and n=69 (All 8 mg); at W96, n=47 (2q8) and n=71 (All 8 mg); patients with inactive polypoidal lesions were defined as those with no polypoidal lesions present OR patients with polypoidal lesions present but both IRF and SRF known to be absent. **BL**, baseline; **CRT**, central retinal subfield thickness; **IRF**, intraretinal fluid; **LOCF**, last observation carried forward; **SRF**, subretinal fluid; **W**, week.



DISCUSSION

- Efficacy was largely maintained with aflibercept 8 mg monotherapy^a in patients with PCV over 2 years
 - Mean change in BCVA and CRT was comparable among the 2q8, 8q12, and 8q16 treatment arms
- Aflibercept 8 mg markedly reduced the proportion of patients with <u>any polypoidal</u> lesions or <u>active</u> polypoidal lesions through 96 weeks
- At Week 96, 72% of patients with PCV treated with aflibercept 8q16 qualified for an extended dosing interval of ≥20 weeks, suggesting extended durability of aflibercept 8 mg compared with aflibercept 2 mg

The safety profiles of aflibercept 8 mg and 2 mg were comparable in the PCV subgroup; no new safety signals were observed in patients with PCV



BCVA gains at Week 96 stratified by baseline PCV status and CNV classification

8q16

- BCVA gains at Week 96 were numerically higher in the PCV subgroup than in patients without PCV^a
- BCVA outcomes at Week 96 were similar across patients stratified by baseline CNV classification^b

PCV Subgroup (ICGA-confirmed)	n	Mean ± SD change in BCVA from BL to Week 96 (LOCF)	Two-sided 95% Cl
2q8	54	+9.6 ± 12.1	6.3, 12.9
8q12	44	+8.4 ± 12.8	4.5, 12.3
8q16	41	+8.2 ± 9.0	5.4, 11.1
Non-PCV Subgroup		Mean ± SD change in	
Non-PCV Subgroup	n	•	Two-sided
(ICGA-confirmed)	n	BCVA from BL to Week 96 (LOCF)	Iwo-sided 95% Cl
.	n 54	BCVA from BL	
(ICGA-confirmed)		BCVA from BL to Week 96 (LOCF)	95% CI

Occult only CNV	n	Mean ± SD change in BCVA from BL to Week 96 (LOCF)	Two-sided 95% Cl
2q8	195	+6.6 ± 10.6	5.1, 8.1
8q12	201	+4.4 ± 13.4	2.5, 6.2
8q16	189	+5.2 ± 11.1	3.6, 6.8
Minimally classic CNV	n	Mean ± SD change in BCVA from BL to Week 96 (LOCF)	Two-sided 95% Cl
2q8	62	+7.4 ± 16.5	3.2, 11.6
8q12	57	+3.5 ± 18.8	-1.5, 8.5

Predominantly classic CNV	n	Mean ± SD change in BCVA from BL to Week 96 (LOCF)	Two-sided 95% Cl
2q8	71	+7.7 ± 15.2	4.1, 11.3
8q12	71	+9.4 ± 14.5	6.0, 12.8
8q16	66	+4.3 ± 16.8	0.2, 8.5

+5.8 ± 15.8

2.0, 9.6

69

FAS, LOCF. N values represent number of patients at BL. aAnalysis included patients with ICGA-confirmed PCV status only. bDetermined by fluorescein angiography/fundus photography. FAS, full analysis set.